Arch Therapeutics and Interpace Biosciences Face Off in Volatility and Valuation

Comparing the financial metrics and institutional ownership of these two biotech firms.

Apr. 12, 2026 at 10:24pm

Got story updates? Submit your updates here. ›

An extreme close-up of complex, metallic biotech machinery and instruments in shades of silver, steel, and chrome, conceptually representing the intricate financial and technological infrastructure underlying the biotech industry.The inner workings of the biotech industry reveal the high-stakes financial and technological challenges facing emerging companies like Arch Therapeutics and Interpace Biosciences.Framingham Today

A head-to-head analysis of Arch Therapeutics and Interpace Biosciences, two publicly traded biotech companies, reveals stark differences in their market volatility, valuation, and institutional ownership.

Why it matters

This comparison provides investors with key insights into the relative risk profiles and growth potential of these two emerging biotech firms, which could help inform investment decisions in the volatile healthcare sector.

The details

Arch Therapeutics has a beta of 4.02, indicating its share price is 302% more volatile than the S&P 500, while Interpace Biosciences has a beta of 0.97, suggesting its stock is 3% less volatile than the broader market. In terms of valuation, Interpace Biosciences has higher revenue and earnings per share than Arch Therapeutics, and trades at a lower price-to-earnings ratio, making it the more affordable of the two stocks. Additionally, Interpace Biosciences has stronger institutional ownership at 5.7% compared to Arch Therapeutics' 6.9%, indicating greater confidence from large investors.

  • The financial data for this analysis is current as of April 12, 2026.

The players

Arch Therapeutics, Inc.

A biotechnology company that develops and markets products based on its AC5 self-assembling technology platform to stop bleeding, control leaking, and manage wounds.

Interpace Biosciences, Inc.

A molecular diagnostics company that provides tests, bioinformatics, and pathology services for evaluating cancer risk in the United States.

Got photos? Submit your photos here. ›

The takeaway

This comparison highlights the trade-offs investors face when considering Arch Therapeutics and Interpace Biosciences. Arch Therapeutics offers higher potential upside but also carries greater market risk, while Interpace Biosciences presents a more stable, affordable option with stronger institutional backing. Investors will need to weigh these factors carefully when deciding which biotech stock best fits their risk tolerance and investment goals.